You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Baxter
McKinsey
Boehringer Ingelheim

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Patent: 8,927,694

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,927,694
Title:Human serum albumin linkers and conjugates thereof
Abstract: Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.
Inventor(s): McDonagh; Charlotte (Winchester, MA), Feldhaus; Michael (Grantham, NH), Huhalov; Alexandra (Cambridge, MA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/130,007
Patent Claims:see list of patent claims

Details for Patent 8,927,694

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2028-11-18 RX search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2028-11-18 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2028-11-18 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2028-11-18 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Merrimack Pharmaceuticals, Inc. (Cambridge, MA) 2028-11-18 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,927,694

Country Patent Number Estimated Expiration
South Africa 201008048   Start Trial
World Intellectual Property Organization (WIPO) 2009126920   Start Trial
World Intellectual Property Organization (WIPO) 2010059315   Start Trial
United States of America 2011059076   Start Trial
United States of America 2012003221   Start Trial
United States of America 2015191545   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.